Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Zhong M, van der Walt A, Stankovich J, Kalincik T, Buzzard K, Skibina O, Boz C, Hodgkinson S, Slee M, Lechner-Scott J, Macdonell R, Prevost J, Kuhle J, Laureys G, Van Hijfte L, Alroughani R, Kermode AG, Butler E, Barnett M, Eichau S, van Pesch V, Grammond P, McCombe P, Karabudak R, Duquette P, Girard M, Taylor B, Yeh W, Monif M, Gresle M, Butzkueven H, Jokubaitis VG.
Zhong M, et al. Among authors: kermode ag.
Mult Scler. 2022 May;28(6):958-969. doi: 10.1177/13524585211049986. Epub 2021 Oct 8.
Mult Scler. 2022.
PMID: 34623947